Treatment-resistant seizures. Epilepsy, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Eligible treatment-resistant epileptic patients are supposed to receive memantine. In fact, in this group, patients are prescribed memantine at a dose of 10 mg at n
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Treatment-resistant epileptic patients
Exclusion criteria
Exclusion criteria: Patients with brain anatomical problems such as temporal sclerosis and cerebral encephalitis Patient with a history of intracranial hemorrhage, stroke, acute ischemic attack, concussion, and cerebral vascular thrombosis Chronic kidney disease Chronic liver disease such as Cirrhosis and ascites Pregnancy and lactation History of cardiovascular disease such as myocardial infarction, angina pectoris, scleroderma, systemic vascular hypertension, and pulmonary arterial hypertension History of gastrointestinal bleeding and inflammatory bowel disease Active gastrointestinal ulcer Concomitant use of medications that increase the risk of bleeding, such as anticoagulants and antiplatelets Ages over 55 years old and under 18 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure frequency. Timepoint: baseline and month 6. Method of measurement: Clinical outcome assessment in seizure frequency changes according to a questionnaire developed by a neurologist.;Serum interleukin 1 level. Timepoint: baseline and month 6. Method of measurement: Patients are evaluated at time intervals of zero (baseline) and month 6 to check the level of the inflammatory factor interleukin-1 in taken blood samples. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Mohammadgholizad
Ardabil University of Medical Sciences
Outcome results
None listed